Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Thursday, September 26, 2013

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Renewal of DARPA Dialysis-Like Therapeutics Contract

SAN DIEGO - September 26, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projects Agency (DARPA) has exercised an option agreement to proceed with year-three of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.

The third year of Aethlon's DLT contract contains eight milestones representing a potential of $1,534,099 in revenue opportunity. To date, Aethlon has invoiced $3,188,131 to DARPA for achieving fourteen of sixteen milestone objectives targeted in the first two years of the DLT program.
The goal of the DLT program is to develop a portable device that removes "dirty" blood from the body, separates harmful agents, and returns "clean" blood to the body in a manner similar to dialysis treatment of kidney failure. The resulting device would decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States annually. In the DLT program, Aethlon has been contracted to utilize the Aethlon ADAPT™ system to create an extracorporeal blood purification cartridge that selectively eliminates sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The Aethlon ADAPT™ converges advanced plasma membrane technology with high affinity drug agents to allow the selective yet rapid clearance of disease targets from the entire circulatory system without damaging blood cells or removing particles essential for health. Aethlon has also been contracted to develop a novel blood circulatory instrument that will deliver ADAPT™ based and other therapeutic filtration devices without systemic anticoagulants normally required in extracorporeal therapies.
Beyond the civilian need for anti-sepsis therapies, the device proposed in the DLT program would play an important role in saving the lives of wounded U.S. military personnel, as infection leading to sepsis is a significant cause of mortality. When sepsis is complicated by shock, approximately half of patients do not survive for 30 days, even if effective antibiotics are used. Unfortunately, the fatality rate from sepsis can be high, given that antibiotic-resistant bacteria are an increasing problem for injured warfighters and military treatment facilities. Bio-agents engineered for resistance against antibiotics also represent a significant threat to both warfighters and citizens. Current culture-based methods of identifying blood-borne pathogens can take 48 hours or longer to identify the offending pathogen, and some blood-borne pathogens do not propagate in culture. Pending these culture results, septic patients are treated with protocol-based broad-spectrum antibiotics. In the event the offending pathogen is resistant to the empirically chosen antibiotic, the fatality rate may increase as much as 9% per hour.
Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). Under the IDE, Aethlon will enroll ten end stage renal disease (ESRD) patients infected with HCV as part of a feasibility study to demonstrate Hemopurifier safety. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and other disease conditions.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Tuesday, September 24, 2013

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.

SAN DIEGO - September 24, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Gercel-Taylor will direct and plan the execution of diagnostic clinical programs and interact with collaborative partners and regulatory authorities.

Aethlon Medical develops therapeutic devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Company is preparing to launch the first U.S. studies of the Aethlon Hemopurifier� as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier� is a first-in-class device that targets the rapid elimination of viruses and cancer glycopathogens, including disease-promoting exosomes from circulation.
Exosome Sciences was recently launched by Aethlon to be a stand-alone organization that pursues exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Dr. Gercel-Taylor stated, "I am very excited to join Exosome Sciences as the Clinical Research Director. This is a very timely opportunity to develop clinically relevant exosome-based assays to enhance patient care with regard to risk assessment, diagnosis and treatment. The conditions are not limited to but include cancer, cardiovascular, and neurodegenerative diseases, in addition to pregnancy complications and viral infections. Exosomes have ideal properties as biomarkers with their stability, ease of isolation and reflecting disease states. The ELLSA will enable the efficient development of disease specific and efficient platforms that can be standardized for clinical utilization. I have been involved in the development and characterization of exosomes since the early days three decades ago. I believe that we are ideally positioned to achieve this goal with our team at Exosome Sciences in collaboration with Aethlon Medical."
About Dr. Gercel-Taylor
Dr. Cicek Gercel-Taylor has been a pioneer in the field of exosome biology and in defining their nucleic acid and protein cargoes. She previously worked at the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992, and also is the Resident Research Coordinator. Her main research interest is in gynecological cancers, where she investigates the consequences of exosomes on genetic and epigenetic alterations induced in normal host target cells. She has explored the role of endogenous and exogenous hormones in modulating exosomal cargoes and the resulting effects on pathologic processes. A significant part of these investigations includes the identification and characterization of clinically relevant biomarkers, specifically proteomic and miRNA content of pathology-derived exosomes. Dr. Gercel-Taylor is the wife of Dr. Douglas Taylor, who was recently appointed Chief Scientific Officer of Exosome Sciences.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT� System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT� product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Medical Technology Q&A with Chairman and CEO of Aethlon Medical (OTCQB: AEMD) Discussing Launch of New Subsidiary, Exosome Sciences, Inc.

Point Roberts, WA, New York, NY - September 24, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues an exclusive Q&A with Jim Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCQB:AEMD). Mr. Joyce discusses the recent launch of its new Exosome Sciences, Inc. (ESI) and what that potentially represents to Aethlon and its shareholders.

Q: Investorideas.com
Jim on September 12 th you announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon. Can you tell investors the focus behind the subsidiary and why the timing was right to launch now?
A: Jim Joyce, Chairman and CEO
The rationale for launching Exosome Sciences was driven by the belief we could transform an unvalued asset into a substantially valued asset that would benefit our shareholders. As the focus of Aethlon Medical is therapeutic devices, the market had little reason to assign any value to candidate diagnostic products as our resources are going to be dedicated toward clinical progression and future commercialization of the Aethlon Hemopurifier® and other pipeline therapies. Especially, now that FDA has approved an IDE that allows us to initiate the first human clinical studies of our Hemopurifier® in the United States.
Still, it became increasingly clear that we needed to leverage our proprietary techniques to isolate and quantify exosomes before the window for related diagnostic innovation began to close. It was also hard to ignore the lofty valuations being awarded to other similar-stage molecular diagnostic organizations. So, we launched Exosome Sciences as a stand-alone entity and hired the best-known researchers in the exosome field to unlock the value of our technology and build an expansive pipeline of urine and blood based diagnostic products.
Q: Investorideas.com
Can you explain to investors what Exosomes are and how they play a role in cancer diagnostics and treatment?
A: Jim Joyce, Chairman and CEO
Sure, but I would first like to share that when we first initiated our exosome research programs, the vast majority of the medical community considered these particles to be nothing more than cellular debris with no biological function. In fact, at the time only a handful of labs were thinking about the role of exosomes. Today, it appears our early entry into the field may pay off as the medical community clearly recognizes that exosomes are vital therapeutic and diagnostic targets. In fact, there are now industry conferences and associations dedicated solely to exosome research.
As it relates to the exosome-related objectives of Aethlon Medical, we utilize our Hemopurifier® to target the elimination of circulating tumor-secreted exosomes as an adjunct therapy to improve cancer treatment outcomes. Our strategy addresses a significant unmet medical need as researchers have discovered that exosomes suppress the immune system of cancer patients and they facilitate tumor growth, seed the spread of metastasis, and contribute to drug resistance. Our hope is that exosome elimination saves lives by tipping the therapeutic balance in favor of the patient.
In regards to the diagnostic focus of our Exosome Sciences subsidiary, we are advancing exosome-based tools to better diagnose and monitor the progression of cancer and other life-threatening disease conditions. As it turns out, exosomes transport markers specific to the origin disease into bodily fluids, including the blood and urine where they can be easily assessed. Our objective is to introduce non-invasive liquid biopsies that can provide for the earliest detection or recurrence of cancer and other diseases. Our lead product is an assay that we named ELLSA. So far, ELLSA has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, and breast cancer.
Q: Investorideas.com
Exosome Diagnostics recently announced it entered into a collaboration agreement with Eli Lilly and Company (LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit. Eli Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.
Your core technology, the Aethlon Hemopurifer®, targets the rapid elimination of infectious disease and cancer glycopathogens, including exosomes from circulation. Can you tell us the synergies and benefits of having both a therapeutic technology and a diagnostic division working on such an important area of cancer research? And does having a diagnostic and therapeutic division so tightly focused give your company an edge?
A: Jim Joyce, Chairman and CEO
Excellent question. There is tremendous synergy as the advancements of Exosome Sciences have the potential to become companion diagnostic tools that determine when Hemopurifier® therapy should be administered. As an example, an assay able to detect exosomes underlying breast cancer might define the point when it would be appropriate to initiate Hemopurifier® therapy. This same assay would then be useful in monitoring patient response to therapy and could be utilized to optimize the administration of the Hemopurifier® and other therapeutic regimens.
Q: Investorideas.com
You just reported the appointment of Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc. What does his background bring to the table to help lead this new subsidiary?
A: Jim Joyce, Chairman and CEO
Dr. Taylor is the individual who first discovered tumor-secreted exosomes and is a leading published author in the field. His knowledge, expertise, and stature within the scientific community will be instrumental in developing a product pipeline and establishing strategic industry relationships.
Q: Investorideas.com
In closing, your company has achieved some significant milestones recently for Aethlon Hemopurifer®. For investors new to the company, can you give us the recent highlights?
A: Jim Joyce, Chairman and CEO
Since the beginning of the year, we have been extremely productive. Beyond the formal launch of Exosome Sciences, we formed a team that won a $22 million Department of Defense contract, we reported on positive Hepatitis C (HCV) treatment outcomes from studies conducted overseas, we expanded the potential indications of our Hemopurifier® in cancer, and disclosed the issuance of new patents that further protect our technologies.
However, the most significant milestone by far was FDA approval of an IDE that allows us to initiate clinical studies of HCV patients in the United States. While this took years of effort, the IDE approval unlocks the opportunity to demonstrate the value of our Hemopurifier® on the world’s most important clinical stage.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com

Friday, September 13, 2013

Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Closes up 12% on News of Launch of Exosome Science Subsidiary

Point Roberts, WA, New York, NY - September 13, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a technical trading alert for Aethlon Medical, Inc. (OTCQB: AEMD). The stock closed trading on Thursday at $0.18, up $0.02 or 12.43% on volume of over 400,000 shares following news of a new Exosome Science subsidiary.

The company on Thursday announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Exosomes produced by diseased cells represent an optimal diagnostic target as they are shed into bodily fluids such as urine and blood where they can be easily accessed. Exosomes transport specific disease-origin markers that provide the basis for ESI to establish non-invasive liquid biopsies to diagnose and monitor a wide-range of disease conditions.
Investorideas.com Newswire About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source - www.Investorideas.com

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.

SAN DIEGO - September 13, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Dr. Douglas Taylor has accepted the position of Chief Scientific Officer at Exosome Sciences, Inc. (ESI), a wholly owned diagnostic subsidiary of Aethlon Medical. Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. "We are truly honored that Dr. Taylor has agreed to lead our research endeavors at Exosome Sciences. His pioneering research has been instrumental in establishing an industry for exosome-based diagnostics and therapeutics," stated Aethlon Chairman and CEO, Jim Joyce. The news was first reported through a presentation given by Mr. Joyce at the Exosomes & Circulating Biomarkers 2013 Summit. Mr. Joyce's presentation occurred after the close of market hours on September 12th.

Aethlon Medical develops therapeutic devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Company is preparing to launch the first U.S. studies of the Aethlon Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier® is a first-in-class device that targets the rapid elimination of viruses and cancer glycopathogens, including disease-promoting exosomes from circulation.
Exosome Sciences was established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Dr. Taylor stated, "I am extremely excited about joining Exosome Sciences as their Chief Scientific Officer. I have been pioneering the field of exosome biology for more than 35 years and believe that exosomes represent the ideal disease marker due to their stability in the peripheral circulation and ability to be multiplexed. Exosome-based diagnostics will not only be used in identification and management of a variety of cancers, but also in other pathologies such as viral infections, pregnancy complications, birth defects, cardiovascular and neurodegenerative diseases. No other platform exhibits their potential for patient stratification and real-time monitoring of therapeutic responses. I have a long history of collaboration with scientists at Aethlon Medical and this opportunity will expand that interaction to bring ELLSA based assays to the clinic."
The release of exosomes by viable cells has been demonstrated in multiple cell types and systems. These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids. They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells. Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease conditions as well as monitor disease progression/regression in response to therapy as a means to improve patient management and outcomes. In the oncology field, ESI products will also be positioned to serve as companion diagnostics that determine when to initiate Hemopurifier® therapy or provide real-time monitoring of tumor responses to Hemopurifier® therapy.
About Dr. Taylor
Dr. Taylor discovered and pioneered the field of exosome biology and their role in intercellular communication and immune regulation. He has been in the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992. Dr. Taylor published the initial article describing circulating tumor exosomes/microvesicles in 1979 (Anal. Biochem. 98:53-59, 1979). The research in his laboratory has primarily focused on the release and consequences of exosomes from gynecologic cancer and lung tumors. Over the past 30+ years, Dr Taylor has pioneered the isolation and characterization of circulating tumor-derived exosomes. His work has focused on characterization of circulating exosomes released by tumor cells for their role in immune regulation and induction of a pro-inflammatory tumor microenvironment. His work has demonstrated that the presence of specific circulating exosomal components have potential use as biomarkers for cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Thursday, September 12, 2013

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Launch of Exosome Sciences Subsidiary

SAN DIEGO - September 12, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Exosomes produced by diseased cells represent an optimal diagnostic target as they are shed into bodily fluids such as urine and blood where they can be easily accessed. Exosomes transport specific disease-origin markers that provide the basis for ESI to establish non-invasive liquid biopsies to diagnose and monitor a wide-range of disease conditions.

Aethlon Chairman and CEO, Jim Joyce stated, "As a therapeutic organization, our primary focus is the clinical advancement and future commercialization of the Aethlon Hemopurifer® in the United States and abroad. With this mind, our objective with ESI is to transform a currently dormant and unvalued diagnostic asset into a stand-alone organization that contributes measurable asset value to Aethlon shareholders, yet does not dilute our team's focus away from advancing first-in-class therapeutic devices. It also became clear that the launch of ESI might allow us to leverage recent valuations that have been awarded to molecular diagnostic organizations with novel technology strategies."
Aethlon disclosed that ESI's research facility is being established within a CLIA certified laboratory located in Langhorne, Pennsylvania. The facility is adjacent to the Philadelphia/New Jersey I-95 corridor, which is the home for numerous U.S. biopharmaceutical organizations, including Merck and Johnson & Johnson. The introduction of key ESI researchers who will lead the development and commercialization of next-generation diagnostics will occur through follow-on disclosures.
At present, Aethlon is preparing to launch the first U.S. studies of the Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens, including exosomes from circulation. Exosomes enhance disease progression of viral infections and in cancer trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
Aethlon will contribute diagnostic related technology to ESI, including the Enzyme Linked Lectin Specific Assay (ELLSA), which has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. ELLSA was originally created by Aethlon researchers as a tool to help validate the ability of the Hemopurifier® to capture tumor-secreted exosomes. At the time, effective tools to isolate and quantify exosomes did not exist as few labs conducted exosome research. Since then, an increased understanding of the role of exosomes underlying a wide-range of disease conditions has created a demand for related diagnostic products. As part of the relationship, ESI has agreed to assign any therapeutic related discoveries back to Aethlon Medical. Beyond the potential for future technology advances by ESI researchers, ESI may also in-license related diagnostic IP from collaborative research partners.
The release of exosomes by viable cells has been demonstrated in multiple cell types and systems. These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids. They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells. Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease conditions as well as monitor disease progression/regression in response to therapy as a means to improve patient management and outcomes. In the oncology field, ESI products will also be positioned to serve as companion diagnostics that determine when to initiate Hemopurifier® therapy or provide real-time monitoring of tumor responses to Hemopurifier® therapy.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Thursday, September 5, 2013

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at Exosomes and Circulating Biomarkers 2013 Summit

SAN DIEGO - September 5, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12th. Mr. Joyce's presentation is entitled; "Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer." The presentation will highlight the clinical advancement of the Aethlon Hemopurifier® in treating hepatitis c virus (HCV) and discuss the opportunity to expand therapeutic indications to include cancer based on targeting the elimination of circulating tumor-secreted exosomes. The conference will be held at the Town and Country Resort Hotel in San Diego, California.

Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). Under the IDE, Aethlon will enroll ten end stage renal disease (ESRD) patients infected with HCV as part of a feasibility study to demonstrate Hemopurifier safety. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and other disease conditions.
The conference abstract of the presentation follows:
Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer on 9/12/13 at 3:45pm pacific.
The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar